WO1999033462A1 - 2-aroyl-4-acyl paclitaxel (taxol) analogs - Google Patents
2-aroyl-4-acyl paclitaxel (taxol) analogs Download PDFInfo
- Publication number
- WO1999033462A1 WO1999033462A1 PCT/US1998/027916 US9827916W WO9933462A1 WO 1999033462 A1 WO1999033462 A1 WO 1999033462A1 US 9827916 W US9827916 W US 9827916W WO 9933462 A1 WO9933462 A1 WO 9933462A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- paclitaxel
- butyldimethylsilyl
- analog
- Prior art date
Links
- 0 CC(C(C*OC([C@@]([C@](*)NC(*)=O)O)=O)([C@@](*)[C@@]([C@@]1(*)[C@@](CC2O)OC1)C2(C)C(C1OC(C)=O)=O)O)C1=CC Chemical compound CC(C(C*OC([C@@]([C@](*)NC(*)=O)O)=O)([C@@](*)[C@@]([C@@]1(*)[C@@](CC2O)OC1)C2(C)C(C1OC(C)=O)=O)O)C1=CC 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
Definitions
- the present invention relates to 2-debenzoyl-4-deacetyl paclitaxel, 2- debenzoyl-4-deacetyl-2,4-diacyl paclitaxel analogs thereof, and methods for making the same.
- Taxol is found in the stem bark of the western yew, Taxus brevifolia, as well as in T. baccata and T. cuspidata. Therefore, there is a limited natural supply of paclitaxel.
- tetracyclic taxane nucleus is an important feature in establishing the antineoplastic activity of paclitaxel and analogs thereof, it is desired to alter the ring substituents without disrupting the tetracyclic nucleus in order to develop antineoplastically active derivatives of paclitaxel.
- the complexity of paclitaxel and its analogs makes it difficult to selectively alter substituents.
- taxol analogs retaining the tetracyclic taxane nucleus are those analogs modified at the C-l, C-2, C-4, C-7 and C-13 positions, and derivatives having a protecting group or a hydroxyl group at the C- 10 position (27).
- analogs with improved activity can be prepared by modifications at various functional groups, and several investigators have prepared paclitaxel analogs modified at the 2-position (1-10), at the 4-position (11-15), at the 7-position (16-19), at the 9 and 10 positions (20-21) and at the 14-position (22), among others.
- Baccatin III derivatives (baccatin III is the taxane core of paclitaxel) have also been prepared with substitutions at C-2 and/or C-4 (23).
- 2-debenzoylpaclitaxels can be prepared from 10- deacetylbaccatin III by a process involving protection at C-7, oxidation at C-13, selective debenzoylation at C-2, formation of the cyclic 1,2-carbonate derivative, reaction with an aryllithium, reduction at C-13, and finally coupling of the C-13 side chain.
- a different route to 2-debenzoyl taxoids was developed by Pulicani et al. (8), who were able to prepare 2-debenzoyl docetaxel and certain derivatives by electrochemical reduction of docetaxel followed by reacylation with Butyllithium and an acid chloride.
- 4-Deacetylpaclitaxel has been prepared by ⁇ ommeh et al. (11) and independently by Georg et al. (12).
- ⁇ ommeh et al. prepared 4-deacetylpaclitaxel by treatment of a protected paclitaxel with base under various conditions, and also by a second method in which a C-13 side chain was attached to a suitably protected 4- deacetylbaccatin III.
- Georg et al. prepared 4-deacetylpaclitaxel by attachment of the C-13 side chain to a protected deacetylbaccatin III.
- 4-Deacetylbaccatin III was also prepared by Datta et al.
- C-4 deacetoxypaclitaxel was prepared by Chordia et al. (15) by preparation of 2-debenzoyl-4-deacetyl paclitaxel by treatment of 2-t- butyldimethylsilyl-7-triethylsilylpaclitaxel with Triton B (an organic-soluble base) followed by formation of the cyclic 1,2-carbonate, formation of a xanthate at C-4, opening of the carbonate with phenyllithium, and deprotection. Paclitaxels with modified C-4 acyl substituents have been prepared by Chen et al.
- the preparation of analogs of paclitaxel is an important endeavor, especially in view of paclitaxel' s clinical activity and limited supply.
- the preparation of analogs might result in the synthesis of compounds with greater potency than paclitaxel (thus reducing the need for the drug), compounds with superior bioavailability, or compounds which are easier to synthesize than paclitaxel from readily available sources.
- the present application describes paclitaxel analogs which have modified substituents at both the C-2 and C-4 positions, in particular 2-debenzoyl-2-acyl-4- deacetyl-4-acyl paclitaxel analogs, as well as procedures for preparing these compounds, and intermediates which can be utilized in preparing these compounds.
- the compounds of the present invention have anti-neoplastic activity and may be used to treat patients suffering from cancer, or as intermediates for making compounds which can be used to treat cancer.
- the paclitaxel analogs have improved in vivo activities for use as anticancer agents, are more soluble, and/or have fewer side effects than paclitaxel.
- R j is an aryl or substituted aryl
- R 2 is an aryl or substituted aryl
- R 3 is selected from the group consisting of H, OH, and 00(0)1 ⁇
- R is selected from the group consisting of H, OH, oxyprotecting group (i.e. triethylsiloxy), OR j ., and OC(O)R c , and wherein 1 ⁇ , R b , and R j .
- R $ is selected from the group OH, OC(O)R d , OC(O)OR g and OC(S)SR f ; and R g is selected from the group H and OC(O)R where R ⁇ R e , R f and R are independently selected from the group consisting of alky Is, cycloalkyls, heterocycloalkyls, heterocycloaryls, alkenyls, alkynyls, aryls, and substituted aryls.
- substituted aryl means an aryl independently substituted with one to five (but preferably one to three) groups selected from C ⁇ 6 alkanoyloxy, hydroxy, halogen, C ⁇ 6 alkyl, trifluoromethyl, C j _ 6 alkoxy, aryl, heteroaryl, C 2 _ 6 alkenyl, C g alkanoyl, nitro, amino, cyano, azido, C ⁇ 6 alkylamino, di-C ⁇ 6 alkylamino, and amido.
- Ar is a phenyl or substituted phenyl group and ⁇ is an alkyl, cycloalkyl or an alkoxy group.
- Another preferred embodiment includes compounds having the formula:
- OCOAr wherein Ar is a substituted phenyl and R 7 is an alkyl, substituted alkyl, aryl or substituted aryl group.
- a substituted phenyl group may be alkyl, alkenyl, alkynyl, aryl, heteroaryl and/or may contain nitrogen, oxygen, sulfur, halogens and include, for example, lower alkoxy such as methoxy, ethoxy, butoxy; halogen such as chloro or fluoro; nitro; amino; and keto.
- Figure 1 is an overview of paclitaxel analogs and intermediates and the chemical reactions for converting one into another.
- Figure 2 shows a selection of paclitaxel analogs and intermediates and the chemical reactions for converting one into another.
- Figure 3 shows a selection of paclitaxel analogs and intermediates and the chemical reactions for converting one into another.
- the present invention pertains to paclitaxel analogs having modified substituents at the C2 and C4 positions.
- the paclitaxel analogs may be easier to synthesize than paclitaxel and more abundant.
- R is an aryl or substituted aryl
- R 2 is an aryl or substituted aryl
- R 3 is selected from the group consisting of H, OH, and 00(0)1 ⁇
- R 4 is selected from the group consisting of H, OH, oxyprotecting group (i.e.
- R a , R b , and R p are independently selected from the group consisting of alky Is, aryls, and substituted aryls;
- ⁇ is selected from the group OH, 00(0)1 ⁇ , OC(O)OR e and OC(S)SR f ;
- Rg is selected from the group H and OC(O)R ⁇ , where R ⁇ , R e , R f and R classroom are independently selected from the group consisting of alkyls, cycloalkyls, heterocycloalkyls, heterocycloaryls, alkenyls, alkynyls, aryls, and substituted aryls.
- substituted aryl means an aryl independently substituted with one to five (but preferably one to three) groups selected from C ⁇ _ alkanoyloxy, hydroxy, halogen, C ⁇ g alkyl, trifluoromethyl, C ⁇ 6 alkoxy, aryl, heteroaryl, C 2 _ 6 alkenyl, C ⁇ 6 alkanoyl, nitro, amino, cyano, azido, C ⁇ g alkylamino, di-C j _ 6 alkylamino, and amido.
- R 4 is OH and R 3 is OC(O)CH 3 .
- R $ is OC(O)R d and R d is preferably an alkyl, cycloalkyl or alkoxy group. It is further preferred that, in addition to the above, R ⁇ is OC(O)R g and R is preferably an aryl or substituted aryl group. It is even further preferred that both R j and R 2 be phenyl.
- a further preferred analog is one wherein R ⁇ is OH, R 3 is OC(O)CH 3 and R 5 and Rg are selected from the following combinations:
- R 5 is cyclopropylcarbonyloxy and Rg is selected from the group consisting of -methoxybenzoyloxy, m-azidobenzoyloxy, m-chlorobenzoyloxy, 3,5-dichlorobenzoyloxy, 3,5-difluorobenzoyloxy, and 2,5-dimethoxybenzoyloxy;
- R 5 is methoxycarbonyloxy and R is selected from the group consisting of m-methylbenzoyloxy, m-methoxybenzoyloxy and m-chlorobenzoyloxy;
- R 5 is S-methyldithiocarboxyoxy and R g is selected from the group consisting of m-methoxybenzoyl, m-chlorobenzoyloxy and m-azidobenzoyloxy. It is particularly preferred that the analogs of paclitaxel have a substituted benzoyloxy group at the 2-position of the B-ring and an acyloxy group or an S- alkyl or S-aryldithiocarboxyoxy group at the 4-position of the C-ring, provided that the acyloxy group is not acetyloxy.
- the substituents on the benzoyloxy group be selected from hydrogen, hydroxyl, halogens, alkyls, alkoxys, nitro, cyano, azido, thiol, alkyl thiols, acyls, acyloxy, alkoxycarbonyloxys, diatomics, and linear triatomics.
- the acyloxy group be selected from alkylcarbonyloxy, arylcarbonyloxy, substituted arylcarbonyloxy, cycloalkylcarbonyloxy, heterocycloalkylcarbonyloxy, and alkoxycarbonyloxy.
- the alkyl group of S-alkyldithiocarboxyoxy should be selected from alkyl, cycloalkyl, and heterocycloalkyl, while the aryl group of S- aryldithiocarboxyoxy should be selected from phenyl, substituted phenyl, and heteroaryl.
- a substituted phenyl group may be alkyl, alkenyl, alkynyl, aryl, heteroaryl and/or may contain nitrogen, oxygen, sulfur, halogens and include, for example, lower alkoxy such as methoxy, ethoxy, butoxy; halogen such as chloro or fluoro; nitro; amino; and keto.
- the analogs having the above general formula display an inhibitory effect on abnormal cell proliferation, and have therapeutic properties that make it possible to treat patients who have pathological conditions associated with an abnormal cell proliferation.
- the pathological conditions include the abnormal cellular proliferation of malignant or non-malignant cells in various tissues and/or organs, including, non-limitatively, muscle, bone and/or conjunctive tissues; the skin, brain, lungs and sexual organs; the lymphatic and/or renal system; mammary cells and/or blood cells; the liver, digestive system, and pancreas; and the thyroid and/or adrenal glands.
- pathological conditions can also include psoriasis; solid tumors; ovarian, breast, brain, prostate, colon, stomach, kidney, and/or testicular cancer; Karposi's sarcoma; cholangiocarcinoma; choriocarcinoma; neuroblastoma; Wilm's tumor, Hodgkin's disease; melanomas; multiple myelomas; chronic lymphocytic leukemias; and acute or chronic granulocytic lymphomas.
- the paclitaxel analogs in accordance with the invention are particularly useful in the treatment of non-Hodgkin's lymphoma, multiple myeloma, melanoma, and ovarian, urothelial, oesophageal, lung, and breast cancers.
- the paclitaxel analogs can be utilized to prevent or delay the appearance or reappearance, or to treat these pathological conditions.
- the paclitaxel analogs can be made by the methods disclosed herein and techniques from the conventional organic chemistry repertoire.
- Figures 1-3 which depict processes by which compounds within the scope of the above general formula can be made, are only shown for the purpose of illustration and are not to be construed as limiting the processes to make the compounds by any other methods.
- the present invention provides analogs useful as active agents in effecting an antitumor or antineoplastic effect in a tumor-bearing host. These analogs or their pharamaceutically acceptable salts can be compounded into pharmaceutical formulations for administration to cancer patients. Such formulations will comprise one or more of the active agents of the present invention in combination with pharamaceutically acceptable excipients and/or adjuvants. Contemplated routes of administration are parenteral and oral, though other acceptable means of administration will be obvious to those of ordinary skill in the art.
- the present invention further provides a method for inhibiting, reducing, or eliminating tumors comprising administering to a mammalian, especially a human, tumor bearing host an antitumor effective amount of an analog of the general formula shown above.
- the analogs of the present invention are contemplated to be used in a manner similar to that of paclitaxel, see e.g. Physician's Desk Reference, 49th Edition, Medical Economics, p 682, 1995.
- the dosage, mode and schedule of administration for the analogs of this invention are not particularly restricted; an oncologist skilled in the art of cancer treatment will be able to ascertain, without undue experimentation, an appropriate treatment protocol for administering the analogs of the present invention.
- the analogs will be administered via any suitable route of administration, in particular, parenterally or orally.
- Parenteral administration includes intravenous, intraperitoneal, intramuscular, and subcutaneous administration.
- the doses utilized to implement the methods of the present invention will be similar to those used in administering paclitaxel, taking into account the relative activity of the analogs described herein. It is expected that one of ordinary skill in the art will be able to discern suitable anti-tumor effective doses and regimens for the efficacious administration of the present paclitaxel analogs. It will be understood that such doses vary, depending on the type of administration, the particular product selected, and the profile and particular characteristics of the patient to be treated.
- the desired doses will be those that are therapeutically effective for the treatment of disorders caused by abnormal cell proliferation.
- the analogs of the present invention can be administered as often as necessary in order to obtain the desired therapeutic effect. Some patients may respond rapidly to relatively high or low doses, and then require mild maintenance or no maintenance dose at all. When administered via IV, the dosage may be, for example, in the
- the dosage 2 range of about 20 to about 500 mg/m over 1 to 100 hours. Orally, the dosage may be in the range of 5-1000mg/kg/day of body weight.
- the actual dose used will vary according to the particular composition formulated, the route of administration, and the particular site, host and type of tumor being treated. Many factors that modify the action of the drug will be taken into account in determining the dosage including age, weight, sex, diet and the physical condition of the patient.
- compositions containing an antitumor effective amount of the paclitaxel analogs of the above general formula in combination with one or more pharmaceutically acceptable carriers, excipients, diluents or adjuvants.
- the compositions can be prepared in accordance with conventional methods.
- paclitaxel is formulated for parenteral administration in polyethoxylated castor oil (Cremophor ® ).
- Cremophor ® polyethoxylated castor oil
- formulating paclitaxel or derivatives thereof are also found in, for example, United States Patent Nos. 4,960,790 and 4,814,470, and such examples can be followed to formulate the compounds of this invention.
- analogs of the general formula might be formulated in the form of tablets, pills, powder mixtures, capsules, injectables, storage stable solutions, suppositories, emulsions, dispersions, food premix, and in other suitable forms. They might also be manufactured in the form of sterile solid compositions, for example, freeze dried (lyophilized) and, if desired, combined with other pharmaceutically acceptable excipients. Such solid compositions can be reconstituted with sterile water, physiological saline, or a mixture of water and an organic solvent, such as propylene glycol, ethanol, and the like, or some other sterile injectable medium immediately before use in parenteral administration.
- sterile solid compositions for example, freeze dried (lyophilized) and, if desired, combined with other pharmaceutically acceptable excipients.
- Such solid compositions can be reconstituted with sterile water, physiological saline, or a mixture of water and an organic solvent, such as propylene glycol, ethanol, and the like, or some
- Typical of pharmaceutically acceptable carriers are, for example, manitol, urea, dextrans, lactose, potato and maize starches, magnesium stearate, talc, vegetable oils, polyalkylene glycols, ethyl cellulose, poly(vinylpyrrolidone), calcium carbonate, ethyl oleate, isopropyl myristate, benzyl benzoate, sodium carbonate, gelatin, potassium carbonate, silicic acid.
- the pharmaceutical preparation may also contain nontoxic auxiliary substances such as emulsifying, preserving, wetting agents, and the like as for example, sorbitan monolaurate, triethanolamine oleate, polyoxyethylene monostearate, glyceryl tripalmitate, dioctyl sodium sulfosuccinate, and the like.
- auxiliary substances such as emulsifying, preserving, wetting agents, and the like as for example, sorbitan monolaurate, triethanolamine oleate, polyoxyethylene monostearate, glyceryl tripalmitate, dioctyl sodium sulfosuccinate, and the like.
- One preferred intermediate is derived from the following paclitaxel analog, which can be made by reacting 2'-t-butyldimethylsilyl-7-triethylsilylpaclitaxel with Triton B in dichloromethane:
- the analog has a protecting group at each of the positions C-2' and C-7 and having OH groups at positions C-2 and C-4, and wherein R j and R 2 are independently selected from the group consisting of aryl, substituted aryl and heteroaryl; R 3 is hydroxy or acyloxy; R 4 is trialkylsilyl; and R 7 is trialkylsilyl.
- the intermediate preferably is of a structure such that R j and R 2 are phenyl, R 3 is acetoxy, R is triethylsilyl, and R 7 is t-butyldimethylsilyl.
- a second preferred intermediate is derived from the following paclitaxel analog:
- R j and R 2 are independently selected from the group consisting of aryl, substituted aryl or heteroaryl; R 3 is hydroxy or acyloxy; R, ⁇ is trialkylsilyl; and R 7 is trialkylsilyl.
- the intermediate preferably is of a structure such that R j and R 2 are phenyl, R 3 is acetoxy, R is triethylsilyl, and R 7 is t-butyldimethylsilyl.
- the second intermediate can be formed by reacting 2'-t-butyldimethylsilyl-2-debenzoyl- 4-deacetyl-7-triethylsilylpaclitaxel with carbonyldiimidazole or triphosgene.
- a third intermediate is derived from the following paclitaxel analog:
- R j and R 2 are independently selected from the group consisting of aryl, substituted aryl or heteroaryl; R 3 is hydroxy or acyloxy; R 4 is trialkylsilyl; R 7 is trialkylsilyl; and R 5 is selected from the group consisting of alkyls, cycloalkyls, heterocycloalkyls, heterocycloaryls, alkenyls, alkynyls, aryls, and substituted aryls. It is preferred that the intermediate have a structure such that R j and R 2 are phenyl, R 3 is acetoxy, R 4 is triethylsilyl, and R 7 is t-butyldimethylsilyl.
- the third intermediate may be formed by reacting the second intermediate with a carboxylic acid in the presence of DCC and DMAP.
- a fourth intermediate is derived from the following paclitaxel analog:
- R and R 2 are independently selected from the group consisting of aryl, substituted aryl or heteroaryl; R 3 is hydroxy or acyloxy; R 4 is trialkylsilyl; R 7 is trialkylsilyl; and Rg is selected from alky Is, cycloalkyls, heterocycloalkyls, heterocycloaryls, alkenyls, alkynyls, aryls, and substituted aryls.
- the intermediate preferably has a structure such that Ri and R 2 are phenyl, R 3 is acetoxy, R 4 is triethylsilyl, and R 7 is t-butyldimethylsilyl.
- This intermediate may be synthesized by reacting 2 ' -t-butyldimethylsilyl-2-debenzoyl-4-deacetyl-7-triethylsilylpaclitaxel with a carboxylic acid (RgCOOH) in the presence of DCC and DMAP.
- RgCOOH carboxylic acid
- a fifth intermediate may be formed from the paclitaxel analog compound having the composition:
- Ri and R 2 are independently selected from the group consisting of aryl, substituted aryl or heteroaryl; R 3 is hydroxy or acyloxy; R 4 is trialkylsilyl; R 5 and Rg are independently selected from the group consisting of alkyls, cycloalkyls, heterocycloalkyls, heterocycloaryls, alkenyls, alkynyls, aryls, and substituted aryls; and R 7 is trialkylsilyl.
- the intermediate preferably is of the structure wherein R, and R 2 are phenyl, R 3 is acetoxy, R 4 is triethylsilyl, and R 7 is t- butyldimethylsilyl.
- This intermediate may be synthesized by reacting 2'-t- butyldimethylsilyl-4-deacetyl-7-triethylsilylpaclitaxel with a carboxylic acid under forcing conditions in the presence of DCC and DMAP.
- this intermediate may be synthesized by reacting the third intermediate with lithium hydroxide followed by a carboxylic acid (RgCOOH), DCC and DMAP.
- paclitaxel (1) is converted to its 2 '-t-butyldimethylsilyl-7 -triethylsilyl derivative 2 by treatment in succession with t-butyldimethylsilyl chloride/imidazole and then with triethylsilyl chloride/pyridine.
- Treatment of 2 with Triton B under carefully defined conditions (-78° to -10°, CH 2 C1 2 ) gave the triol 3 (2-debenzoyl-4-deacetyl-2'-t- butyldimethylsilyl-7-trie ⁇ hylsilylpaclitaxel) as a key intermediate.
- This intermediate has been prepared previously by us (15) and by Georg (13).
- Standard workup or “usual workup” used herein includes extraction with a suitable solvent (usually ethyl acetate or methylene chloride), washing the extract with water, drying over magnesium sulfate or sodium sulfate, and evaporation in vacuo. All technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.
- reaction mixture was stirred at -78 °C for 5 minutes and the cooling bath was removed to allow the reaction mixture to warm to -10° (ethylene glycol; dry ice bath).
- the mixture was stirred at -10°C for one hour, and the progress of the reaction was monitored with TLC.
- the TLC analysis revealed first formation of more polar 2-debenzoyl compound (Rf 0.3), that further converted to nonpolar 2- debenzoyl-4-deacetyl compound (Rf 0.5).
- the mixture was diluted with cold CH 2 C1 2 (-40°) and quenched with 5mL 0.1N HCI. The organic layer was separated by washing successively with water, dilute ⁇ aHCO 3 and brine, and drying over Na 2 SO 4 . Concentration under reduced pressure gave a crude residue that was purified by PTLC (silica gel, 1000 m, ethylacetate:hexanes, 2:3) to yield compound 3 (60.7 mg, 65%).
- reaction mixture was stirred either at room temperature or heated on an oil bath at 60° until the starting compound was consumed (TLC analysis, generally 4-16hours).
- the reaction mixture was diluted with EtOAc (lOmL) and filtered through a pad of silica gel and celite. This pad was further washed with EtOAc (lOmL).
- EtOAc filtrate was concentrated on a rotary evaporator to give crude product. Further purification using preparative TLC (silica gel; 500m, hexane:EtOAc; 2:1) gave 2- substituted benzoyl-2'-tert-butyl-7-triethylsilypaclitaxel analogs 5 and 5a respectively (60-90% yield).
- CARBONYD-PACLITAXEL (6b): To a solution of 2'-O-tert-butyldimethylsilyl- 7-O-triethylsilyl-2-debenzoyl-2-(3-azido benzoyl)-4-deacetyl-4-(methoxycarbonyl)- paclitaxel (8.0 mg, 0.007 mmol) in dry THF was added HF-pyridine (0.2 mL) in a Teflon vial. The reaction mixture was stirred at room temperature for 2 hours. The mixture was then diluted with EtOAc (10 mL) and washed thoroughly with dilute sodium bicarbonate, dilute HC1, water and finally brine.
- Taxol A Unique Antineoplastic Agent With Significant Activity in an Advanced Ovarian Epithelial Neoplasms, Ann. Intern. Med, 1989, 111, 273-279.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98965561A EP1067923A4 (en) | 1997-12-31 | 1998-12-30 | 2-aroyl-4-acyl paclitaxel (taxol) analogs |
IL13921898A IL139218A0 (en) | 1997-12-31 | 1998-12-30 | 2-aroyl-4-acyl-paclitaxel (taxol) analogs |
CA002328771A CA2328771A1 (en) | 1997-12-31 | 1998-12-30 | 2-aroyl-4-acyl paclitaxel (taxol) analogs |
AU21002/99A AU759030B2 (en) | 1997-12-31 | 1998-12-30 | 2-aroyl-4-acyl paclitaxel (taxol) analogs |
HU0101457A HUP0101457A3 (en) | 1997-12-31 | 1998-12-30 | Antitumor 2-aroyl-4-acyl paclitaxel analogs and medicaments containing them , their intermediates and method for producing them |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7023497P | 1997-12-31 | 1997-12-31 | |
US60/070,234 | 1997-12-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999033462A1 true WO1999033462A1 (en) | 1999-07-08 |
WO1999033462A9 WO1999033462A9 (en) | 1999-09-30 |
Family
ID=22094031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/027916 WO1999033462A1 (en) | 1997-12-31 | 1998-12-30 | 2-aroyl-4-acyl paclitaxel (taxol) analogs |
Country Status (7)
Country | Link |
---|---|
US (2) | US6476242B1 (en) |
EP (1) | EP1067923A4 (en) |
AU (1) | AU759030B2 (en) |
CA (1) | CA2328771A1 (en) |
HU (1) | HUP0101457A3 (en) |
IL (1) | IL139218A0 (en) |
WO (1) | WO1999033462A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6515151B1 (en) | 1992-12-23 | 2003-02-04 | Bristol-Myers Squibb Company | Method for the preparation of novel sidechain-bearing taxanes and intermediates thereof |
US6750246B1 (en) | 2000-02-03 | 2004-06-15 | Bristol-Myers Squibb Company | C-4 carbonate taxanes |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003053350A2 (en) * | 2001-12-20 | 2003-07-03 | Bristol-Myers Squibb Company | Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability |
US7030253B2 (en) * | 2003-08-07 | 2006-04-18 | Bristol-Myers Squibb Company | Process for preparing 4-alkyl- or 4-aryl-oxycarbonyl paclitaxel analogs and novel intermediates |
WO2005037338A1 (en) * | 2003-10-14 | 2005-04-28 | Cook Incorporated | Hydrophilic coated medical device |
US7601400B2 (en) * | 2005-03-10 | 2009-10-13 | General Electric Company | Liquid electrostatic coating composition comprising corrosion resistant metal particulates and method for using same |
US20060258736A1 (en) * | 2005-05-12 | 2006-11-16 | Bristol-Myers Squibb Company | Dosing regimen |
WO2006124884A2 (en) * | 2005-05-13 | 2006-11-23 | Bristol-Myers Squibb Company | Dosing regimen |
PL217731B1 (en) | 2006-06-01 | 2014-08-29 | Tomasz Byrski | Detection of lowered response for chemotherapy with the use of cytostatics from a group of toxoids |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY110249A (en) * | 1989-05-31 | 1998-03-31 | Univ Florida State | Method for preparation of taxol using beta lactam |
US5175315A (en) * | 1989-05-31 | 1992-12-29 | Florida State University | Method for preparation of taxol using β-lactam |
US5728725A (en) * | 1991-09-23 | 1998-03-17 | Florida State University | C2 taxane derivaties and pharmaceutical compositions containing them |
US5399726A (en) * | 1993-01-29 | 1995-03-21 | Florida State University | Process for the preparation of baccatin III analogs bearing new C2 and C4 functional groups |
US5489601A (en) * | 1991-09-23 | 1996-02-06 | Florida State University | Taxanes having a pyridyl substituted side-chain and pharmaceutical compositions containing them |
HU225294B1 (en) | 1992-12-23 | 2006-09-28 | Bristol Myers Squibb Co | Oxazoline derivatives for synthesis of sidechain-bearing taxanes and preparation thereof |
US5973160A (en) * | 1992-12-23 | 1999-10-26 | Poss; Michael A. | Methods for the preparation of novel sidechain-bearing taxanes |
IL108444A0 (en) * | 1993-01-29 | 1994-04-12 | Univ Florida State | C2 taxane derivatives and pharmaceutical compositions containing them |
US5399729A (en) * | 1993-08-31 | 1995-03-21 | Arco Chemical Technology, L.P. | Esterified alkoxylated polyol fat substitutes having high primary ester content |
-
1998
- 1998-12-30 AU AU21002/99A patent/AU759030B2/en not_active Ceased
- 1998-12-30 IL IL13921898A patent/IL139218A0/en unknown
- 1998-12-30 WO PCT/US1998/027916 patent/WO1999033462A1/en active Search and Examination
- 1998-12-30 HU HU0101457A patent/HUP0101457A3/en unknown
- 1998-12-30 EP EP98965561A patent/EP1067923A4/en not_active Withdrawn
- 1998-12-30 US US09/223,193 patent/US6476242B1/en not_active Expired - Fee Related
- 1998-12-30 CA CA002328771A patent/CA2328771A1/en not_active Abandoned
-
2002
- 2002-08-02 US US10/210,018 patent/US20030036661A1/en not_active Abandoned
Non-Patent Citations (3)
Title |
---|
GEORG G I, ET AL.: "SELECTIVE C-2 AND C-4 DEACYLATION AND ACYLATION OF TAXOL: THE FIRSTSYNTHESIS OF A C-4 SUBSTITUTED TAXOL ANALOGUE", TETRAHEDRON LETTERS, PERGAMON, GB, vol. 35, no. 48, 1 January 1994 (1994-01-01), GB, pages 8931 - 8934, XP002917017, ISSN: 0040-4039, DOI: 10.1016/0040-4039(94)88392-0 * |
See also references of EP1067923A4 * |
SHU-HUI CHEN, ET AL.: "NOVEL C-4 PACLITAXEL (TAXOL) ANALOGS: POTENT ANTOTUMOR AGENTS", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 05, no. 22, 1 January 1995 (1995-01-01), AMSTERDAM, NL, pages 2741 - 2746, XP002917016, ISSN: 0960-894X, DOI: 10.1016/0960-894X(95)00453-Z * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6515151B1 (en) | 1992-12-23 | 2003-02-04 | Bristol-Myers Squibb Company | Method for the preparation of novel sidechain-bearing taxanes and intermediates thereof |
US6750246B1 (en) | 2000-02-03 | 2004-06-15 | Bristol-Myers Squibb Company | C-4 carbonate taxanes |
Also Published As
Publication number | Publication date |
---|---|
AU759030B2 (en) | 2003-04-03 |
EP1067923A1 (en) | 2001-01-17 |
IL139218A0 (en) | 2001-11-25 |
US6476242B1 (en) | 2002-11-05 |
HUP0101457A2 (en) | 2001-12-28 |
WO1999033462A9 (en) | 1999-09-30 |
US20030036661A1 (en) | 2003-02-20 |
EP1067923A4 (en) | 2002-11-13 |
CA2328771A1 (en) | 1999-07-08 |
AU2100299A (en) | 1999-07-19 |
HUP0101457A3 (en) | 2003-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI111634B (en) | Process for the preparation of therapeutically useful 7-deoxotaxol, intermediates and processes for the preparation of intermediates | |
US5635531A (en) | 3'-aminocarbonyloxy paclitaxels | |
US6750246B1 (en) | C-4 carbonate taxanes | |
EP0747385B1 (en) | Prodrugs of paclitaxel derivatives | |
US6201140B1 (en) | 7-0-ethers of taxane derivatives | |
US5840929A (en) | C4 methoxy ether derivatives of paclitaxel | |
US5739359A (en) | Methods for preparing 1-deoxy paclitaxels | |
AU3477797A (en) | 7-deoxy-6-substituted paclitaxels | |
US5773464A (en) | C-10 epoxy taxanes | |
US6476242B1 (en) | 2-aroyl-4-acyl paclitaxel (Taxol) analogs | |
US20050250844A1 (en) | Methods of treating cancer using C-4 carbonate taxanes | |
US6362217B2 (en) | Taxane anticancer agents | |
WO2002078690A2 (en) | Taxoid anti-tumor agents and pharmaceutical compositions thereof | |
AU724591B2 (en) | 7-methylthiooxomethyl and 7-methylthiodioxomethyl paclitaxels | |
AU2001245582A1 (en) | Taxane anticancer agents | |
WO1998047360A1 (en) | 7-sulfur substituted paclitaxels | |
WO1999032109A1 (en) | 7-deoxy-6-nitrogen substituted paclitaxels | |
RU2419622C2 (en) | Taxol derivatives with anticancer activity | |
WO1998000419A1 (en) | Ortho-ester analogs of paclitaxel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/3-3/3, DRAWINGS, REPLACED BY NEW PAGES 1/3-3/3; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998965561 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2328771 Country of ref document: CA Ref document number: 2328771 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 21002/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 139218 Country of ref document: IL |
|
WWP | Wipo information: published in national office |
Ref document number: 1998965561 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 21002/99 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998965561 Country of ref document: EP |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) |